NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (237)	11/17/1997 10:43:00 PM
From: Miljenko Zuanic	Read Replies (1) of 328

Peter: I guess NXTR followers disappeared after last deep. Yesterday I was wandering what triggered one point END-DAY rise for NXTR. I guess today news is answers: biz.yahoo.com I WISH THAT ONE DAY I WILL BE ABLE TO READ COMPANIES, NOT ONLY NXTR- ANY AND EVERY COMPANY, PRESS ANNOUNCEMENT WHICH CAN CLEARLY STATED WHAT IS GOING ON! In this MiKasome UTI's PII trials what will first group receive: Amikacin (I guess not) or MiKasome. What will be dose of MiKasome in second group? I guess 70 mg/kg or equal to total dose in first group. I guess this is open label randomized comparative trials! Will NXTR tried different single MiKasome dose? GOD help me on my criticism, but this people have M.D. , PhD,... and they do not know how to compose few sentences for news announcement. What we are, dome ones! This is actually very good news. FDA allowed second IND application and clinicals to start from PII based an excellent safety data from PI trials on AIDS patients. Complicated UTI is serious disease and amikacin has kidney toxicity. MiKasome does not have this side effects problems which is big plus. Hope MiKasome will show efficiency, as it has show in some AIDS patients. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next